Kyowa Kirin Co., Ltd.
4151・Prime Market・Pharmaceuticals
Governance
A company with a Board of Corporate Auditors (scheduled to transition to a Company with an Audit and Supervisory Committee upon approval at the Annual General Meeting of Shareholders on March 19, 2026). The company has established a hybrid governance structure with 9 directors (including 5 independent outside directors, a majority), a Board of Directors chaired by an independent outside director, and a voluntary Nomination and Compensation Advisory Committee (chaired by an independent outside director, with independent outside officers forming a majority).
Risk Management
Under the "Kyowa Kirin Group Risk Management Basic Policy," the company implements risk management across the entire group, including sustainability risk. In compliance with the Three Lines Model advocated by the IIA, a governance structure has been established through the risk management oversight organization, the internal audit department (third line), the Group Risk Management Committee, and other bodies, with audit results reported periodically to the Board of Directors and Audit & Supervisory Board Members.
Shareholder Returns
The annual dividend forecast for FY2026 (ending December 2026) is ¥70 per share (interim ¥35 + year-end ¥35), an increase of ¥8 from the previous fiscal year's actual dividend of ¥62. There has been no revision to the dividend forecast. A small amount of share buybacks was conducted (¥3 million in the current quarter).
Dividend Policy
From FY2026 onward, the dividend policy is based on a DOE of 4% or more combined with progressive dividends. The annual dividend forecast for FY2026 (ending December 2026) is ¥70 per share (interim ¥35 + year-end ¥35). The actual dividend for the previous fiscal year was ¥62 (interim ¥30 + year-end ¥32).
ESG
On climate change response, the company has set CO2 reduction targets aligned with the SBT 1.5°C target, achieving a 70% reduction in Scope 1+2 emissions (versus 2019) and a 98% renewable electricity adoption rate as of the end of FY2025 (ending March 2026). In human capital, initiatives include the dissemination of the "KABEGOE Principles," promotion of DE&I (targeting a female manager ratio of 30% or more by 2030), and certification as an Excellent Health Management Corporation for nine consecutive years. The company has identified product quality, stable supply, improved access to medicines, and strengthened corporate governance as materiality issues, and is advancing the dual pursuit of social value and economic value under CSV management.
Last updated: March 10, 2026